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 Abstract 
 
Most sedative-hypnotics used in insomnia treatment target the γ-aminobutyric acid (GABA)A 
receptors. A vast repertoire of GABAA receptor subtypes was identified and displays specific 
electrophysiological and functional properties. GABAA-mediated inhibition traditionally refers to 
“phasic” inhibition, arising from synaptic GABAA receptors, which transiently inhibit neurons. 
However, there is growing evidence that peri/extra-synaptic GABAA receptors are continuously 
activated by low GABA concentrations and mediate a “tonic” conductance. This slower type of 
signaling appears to play a key role in controlling cell excitability. This review aims at summarizing 
recent knowledge on GABA transmission, including the emergence of tonic conductance, and 
highlighting the importance of GABAA receptor heterogeneity. The mechanism of action of sedative-
hypnotic drugs and their effects on sleep and the electroencephalogram (EEG) will be reported. 
Furthermore, studies using genetically-engineered mice will be emphasized, providing insights into 
the role of GABAA receptors in mechanisms underlying physiological and pharmacological sleep. 
Finally, we will address the potential of GABAA receptors pharmacology for the treatment of 
insomnia. 
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 1. Introduction 
It is a common experience that sleep is critical to recover from tiredness and thereby has 
potent restorative virtues. Poor quality of sleep, typical for insomnia, has many adverse effects on 
daily life. Insomnia is highly prevalent. It is defined by complaints of disturbed sleep in the presence 
of adequate opportunity for sleep. The disturbances can consist of one or several features including 
difficulty in initiating sleep, maintaining sleep, waking up too early and, non-restorative or poor-
quality sleep (Mendelson et al., 2004; Roth, 2007). It has been proposed that insomnia is a 
hyperarousal disorder which could reflect a deficit in sleep homeostasis (Borbély & Achermann, 2005; 
Vgontzas, 2005). Pharmacology plays an important role in insomnia therapy, targeting several 
transmitter and peptide systems, including γ-aminobutyric acid/GABAergic, serotonergic, as well as 
histaminergic and hypocretin/orexinergic systems (Wafford & Ebert, 2008). Past and current 
treatments have been dominated by sedative-hypnotic drugs acting at GABAA receptors, including the 
traditional benzodiazepines (BZ) and non-BZ drugs (i.e., “Z”-drugs: zolpidem, zaleplon, zopiclone, 
eszopiclone).  
The classical view of neuronal activity relies on the balance between two modes of 
transmission, excitation mediated by glutamate and inhibition mediated by GABA. GABA, the 
predominant inhibitory transmitter in the brain, plays a key role in neuronal firing patterns and activity 
of neuronal networks. In the central nervous system, GABA exerts its effect via ionotropic GABAA 
and GABAc receptors, and metabotropic GABAB receptors (Barnard et al., 1998; Bowery, 2006). 
GABA
B
BB receptors are insensitive to drugs which target GABAA and GABAc receptors are primarily 
expressed in retina and optical layers of the superior colliculi. This review will thus focus on GABAA 
receptors. Since their first characterization as “benzodiazepine”-receptors in the late 70s (Braestrup et 
al., 1977; Möhler & Okada, 1977), GABAA receptors have been shown to be a major site for 
clinically-relevant drugs, including barbiturates, some general anesthetics, as well as ethanol (Mohler, 
2006). A vast repertoire of GABAA receptor subtypes was identified, underlying the complexity of 
GABAA-mediated transmission. Recently, the emergence of tonic inhibition, mediated by GABAA 
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 receptors located outside the synaptic junction, challenged the traditional view of GABAA-mediated 
transmission. This novel type of conductance may provide further insights into the understanding of 
sleep mechanisms, as well as the effects of sedative-hypnotic drugs on sleep. 
The following review will first recapitulate properties of GABAA receptors underlying the 
heterogeneity of GABAA-mediated transmission. Then the knowledge on pharmacological profiles of 
sedative-hypnotic drugs and their effects on sleep will be summarized. Studies using genetically-
engineered mice providing insights into the role of GABAA receptors in mechanisms underlying sleep 
will be highlighted. 
 
 
 
2. Heterogeneity of GABAA receptors and GABAA-mediated transmission 
GABA is released from the presynaptic neuron into the synaptic cleft. It exerts its action by 
binding to two cognate sites on the extracellular surface of GABAA receptors. The activation of the 
ligand-gated ion channel results in a very rapid increase in permeability for chloride ions, leading to 
membrane hyperpolarization and inhibition of excitability (Maconochie et al., 1994).  
In addition to the fast inhibitory transmission, there is increasing evidence that GABAA chloride 
conductance can depolarize postsynaptic neurons and may have excitatory actions. When combined 
with other depolarizing inputs within a specific time window, activation of GABAA receptors may 
facilitate action potential generation. Therefore, GABAergic inputs at the same synapse may result in 
different actions depending on intracellular chloride concentrations at the site of GABAergic input, as 
well as the spatio-temporal summation with other inputs (Gulledge & Stuart, 2003; Marty & Llano, 
2005). Furthermore, but beyond the scope of this review, GABAA receptors not only mediate their 
action at the level of postsynaptic neurons but also presynaptically (Kullmann et al., 2005). 
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 2.1. Heterogeneity of subunits forming a variety of GABAA receptors. 
GABAA receptors are pentameric hetero-oligomers, the subunits’ assembly forming the 
central ion channel. Several subunit classes have been identified in mammalian genomes, each of the 
subunits displaying several isoforms (α1-6, β1-3, γ1-3, δ, ε, π, ρ1-3, and θ; (Barnard et al., 1998; 
Whiting et al., 1999). The potential permutations forming pentameric oligomers are considerable. 
However, not all subunits co-assemble to form GABAA subtypes. For instance, δ and γ subunits are 
mutually exclusive (Sieghart et al., 1999). The δ, ε and π subunits are believed to substitute for the γ 
subunit, whereas the θ may replace the β subunit. The subunit composition and stochiometry of native 
GABAA receptors is not yet completely elucidated. The properties of native GABAA receptors could 
be recapitulated in vitro when α, β and γ subunits were co-expressed (Pritchett et al., 1989). Further 
available evidence favors GABAA receptors containing α-, β-subunits, and in the vast majority of 
cases a γ subunit in a 2:2:1 stochiometry (Chang et al., 1996; Tretter et al., 1997). A 2:1:2 
stochiometry has also been reported (Backus et al., 1993). The majority of receptors appear to consist 
of a single α isoform. However, a minority of populations containing α1α2, α1α3, α1α5, α2α3 or α3α5 
pairs have been detected (Barnard et al., 1998).  
 
 
2.2. Specific anatomical expression of GABAA subtypes.  
The assembly of subunits forming the GABAA receptors also depends on the regional distribution 
of each subunit in the brain (Wisden et al., 1988; Fritschy & Mohler, 1995; Pirker et al., 2000). 
Furthermore, the cellular (somato-dendritic versus axonal) and subcellular localization of GABAA 
receptors on neurons contributes to the complexity of GABAA receptor heterogeneity (Somogyi et al., 
1989; Kullmann et al., 2005; Trigo et al., 2008). While α1-, α2-, α3-containing subtypes are mainly 
localized synaptically, these receptor subtypes are also found outside the synapse (Table 1) (Somogyi 
et al., 1989). The δ-containing receptors (i.e., α4βxδ, α1βxδ, and α6βxδ) appear to be predominantly or 
exclusively peri- and/or extra-synaptic, though morphological evidence for such extrasynaptic 
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 localization is scarce (Nusser et al., 1998; Fritschy & Brunig, 2003). The α5-containing receptors are 
mainly extrasynaptic. Nevertheless, there is functional and morphological evidence that a pool of α5-
containing receptors also concentrates at GABAergic synapses located on dendrites (Serwanski et al., 
2006; Ali & Thomson, 2008). This segregation between synaptic and extrasynaptic GABAA receptors 
is important since they are involved in mediating two distinct forms of GABAA-transmission 
(Semyanov et al., 2004; Mody, 2005).  
 
 
2.3. Two distinct modes of GABAA-mediated transmission: phasic versus tonic inhibition  
GABAA-mediated transmission traditionally refers to the transient -“phasic”- inhibitory 
postsynaptic currents (IPSCs) following the activation of synaptic receptors by high concentration 
(mM range) of GABA released from presynaptic nerve terminals (Maconochie et al., 1994). However, 
there is growing evidence that extrasynaptic GABAA receptors are continuously activated by low (<50 
μM) GABA concentration and thereby mediate a persistent -“tonic”- inhibition (Fig. 1). Though the 
discovery of tonic inhibition is relatively recent, new insights emphasize the importance of this 
transmission (Semyanov et al., 2004; Cavelier et al., 2005; Farrant & Nusser, 2005; Mody, 2005; 
Walker & Semyanov, 2008).  
Electrophysiological recordings in rodent brain slices demonstrated the presence of GABAA-
mediated tonic inhibition in several regions and specific cell-types, including cerebellar granule cells 
(Brickley et al., 1996), relay neurons of the ventrobasal thalamic nuclei (Porcello et al., 2003; Belelli 
et al., 2005; Jia et al., 2005), pyramidal cells of neocortical layers II-III and V (Drasbek & Jensen, 
2006; Drasbek et al., 2007; Yamada et al., 2007; Vardya et al., 2008), as well as the hippocampal 
dentate gyrus granule cells and the hippocampal interneurons of the molecular layer (Glykys et al., 
2008). The occurrence of tonic currents correlates with the regional and extrasynaptic distribution of 
specific GABAA subtypes (Table 1, Fig.2). The majority of extrasynaptic receptors is believed to 
contain the δ-subunit. This subunit shows high expression levels in the cerebellum, numerous thalamic 
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 relay nuclei, the outer layers of the cortex (I-III) and the dentate gyrus (Wisden et al., 1988; Fritschy & 
Mohler, 1995; Peng et al., 2002). The δ subunit is preferentially associated with the α4 subunit (Sur et 
al., 1999) and the α4 expression pattern parallels that of the δ subunit. Nonetheless, a fraction of γ2-
containing receptors located extrasynaptically also contributes to tonic conductance when activated by 
ambient GABA.  
 
 
2.4. GABAA subtypes display distinct electrophysiological properties. 
The subcellular segregation of specific GABAA subtypes together with the biophysical properties 
of GABAA receptors (i.e., concentration of ligand to induce the half maximal response, rate and extent 
of activation, desensitization and deactivation of the current) define their respective contribution to 
phasic or tonic conductance (for review, Vicini & Ortinski, 2004; Farrant & Nusser, 2005). The 
subunit composition of the receptor has considerable impact on the biophysical properties of the 
chloride channel. The type of α-subunit determines the kinetics of receptor activation (Verdoorn et al., 
1990). δ-containing receptors (i.e., α6β3δ and α4β3δ) require low concentrations of GABA to reach 
50% activation of the maximal response (EC50 = ~0.3-0.7 μM; (Brown et al., 2002; Farrant & Nusser, 
2005). In contrast, γ2-containing receptors (e.g. α 1β3γ2 or α2β3γ2 combinations) have a lower 
affinity for GABA and thus higher EC50 (~6-14 μM). δ containing receptors display lower rate of 
desensitization compared to γ-containing receptors, and the rate and extend of desensitization is also 
dependent on the type of α-subunit present.  
Phasic and tonic conductance can be modulated by changes in the number and properties of 
receptors, as well as GABA release and uptake. Extrasynaptic receptors respond to low, persistent 
concentration of GABA in the extracellular space, potentially due to spillover from the synapse as well 
as release from astrocytes (Fig.1) (Walker & Semyanov, 2008). Other amino acids, such as taurine and 
β-alanine, may also be involved in the generation of tonic currents (Cavelier et al., 2005; Jia et al., 
2008; Walker & Semyanov, 2008). Elevated ambient GABA (possibly drug-induced) or actions of 
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 allosteric modulators, such as BZ and Z-drugs, may recruit other extrasynaptic and/or synaptic 
receptors in a given neuronal circuit which may contribute tonic conductance. 
Overall, the affinity for GABA, the rate and extent of desensitization, together with the subcellular 
segregation of distinct GABAA subtypes are key parameters underlying their differential activation and 
their contribution to phasic or tonic conductance.  
 
 
2.5. Physiological significance of phasic and tonic inhibition. 
Phasic inhibition, mediated by the activation of synaptic GABAA receptors is characterized by 
IPSC currents that peak and decay within milliseconds (Mody et al., 1994). This transient activation is 
due to the rapid clearance of GABA from the synaptic cleft by active transporters and simple diffusion 
(Grabauskas, 2005).  
In contrast, the persistent activation of extrasynaptic receptors may result in an increase of 
membrane conductance (Semyanov et al., 2004; Cavelier et al., 2005; Farrant & Nusser, 2005), 
thereby reducing the change in membrane voltage elicited by excitatory input currents. Tonic 
conductance was proposed to decrease spatial and temporal integration of excitatory signals (Pouille & 
Scanziani, 2001; Cavelier et al., 2005). In cerebellar granule cells, frequency of action potential firing 
induced by an excitatory input can be altered upon pharmacological blockade of tonic inhibition 
(Hamann et al., 2002). Tonic inhibition in this cell-type generated a mean inhibitory conductance 3-
fold larger than currents produced by high frequency action potentials evoked by vesicular release of 
GABA. Moreover, it contributed to ~90% of the total inhibition (Hamann et al., 2002). The magnitude 
of tonic conductance varies among cell-types. 
In summary, phasic conductance rapidly and transiently inhibits neuronal excitability. In contrast, 
the effects of the tonic “background” conductance, a slower type of signaling, reduce the capability of 
excitatory stimuli to generate action potentials. Thereby, tonic conductance modulates neuronal firing 
rates and adjusts the excitability of neuronal networks. This property of establishing a “baseline” 
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 excitability level of neuronal networks raises the intriguing possibility that such a mechanism may be 
involved in sleep and cognition. 
 
 
2.6 Tonic inhibition is present in brain regions and cell populations relevant for sleep. 
The high expression levels of the extrasynaptic α4βxδ subtype, as well as the presence of GABAA-
mediated tonic currents in the thalamus and cortex (see section 2.3) are of particular interest in the 
context of sleep physiology (Table 1, Fig. 2).Tonic currents represent 80 % of the total GABAA-
mediated transmission in relay cells of the thalamus, while no tonic currents were observed in the 
thalamic reticular nucleus (Belelli et al., 2005). The thalamus and cortex form a functional network via 
integrated recurrent loops, enabling the synchronized activity of large-scale ensembles of neurons 
which generate specific brain oscillations (Steriade et al., 1986; Jones, 2002; Steriade, 2003). The type 
of firing of thalamo-cortical neurons in vivo is behavioral-state dependent. Low-threshold bursting is 
associated with non-rapid eye movement (NREM) sleep, while tonic firing is typical for waking. 
Blocking tonic inhibition favors tonic firing in thalamic slices (Cope et al., 2005). On the other hand, 
pharmacological enhancement of tonic inhibition hyperpolarized thalamic relay neurons. Modulation 
of tonic conductance also alters the temporal precision of low-threshold burst firing (Bright et al., 
2007). Interestingly, widespread changes in GABA release across the thalamus increased tonic 
inhibition in the thalamic relay neurons while a local increase in GABA had no effect (Bright & 
Brickley, 2008). By adjusting the excitability of neuronal circuitries, tonic inhibition may play an 
important role in modulating the magnitude and frequency of network oscillations characterizing 
vigilance states and their associated behaviors. 
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 3. Pharmacological profiles of sedative-hypnotic drugs targeting GABAA receptors and their 
effects on sleep 
The structural complexity of GABAA receptors, the multiple receptor subtypes with distinct 
electrophysiological properties (channel kinetics, affinity for GABA, rate of desensitization, phasic 
versus tonic conductance), and specific regional, cellular and subcellular distribution, underlie their 
functional properties and pharmacological profiles. 
Most sedative-hypnotics used in the treatment of insomnia target the GABAA receptors. It is 
commonly accepted that anxiolytic, anticonvulsant, myorelaxant, as well as amnestic, sedative and 
hypnotic actions of these drugs are due to their “general” inhibitory effect on neuronal activity 
(Rudolph & Mohler, 2004). Understanding how these various sedative-hypnotic drugs enhance phasic 
and/or tonic GABAA-mediated transmission is of particular importance. 
 
 
3.1 Binding sites on the GABAA receptors & pharmacological profiles of sedative-hypnotic drugs.  
GABA binds at the interface between α and β subunits. BZs and Z-drugs act via the so-called BZ 
binding site located at the interface between α and γ subunits (Sigel & Buhr, 1997), and thereby 
specifically bind to γ-containing receptors. In contrast, GABAA agonists bind to the same binding sites 
as GABA, between the α and β subunits (Amin & Weiss, 1993; Smith & Olsen, 1994). The δ subunit 
was recently reported to confer high agonist sensitivity (You & Dunn, 2007). 
The requirement of the γ subunit for the binding infers that BZs and Z-drugs will act on the 
majority of GABAA receptors (Table 1). BZ and Z-drugs are positive allosteric modulators, i.e., they 
enhance the GABA-induced chloride current. They have little intrinsic activity in the absence of 
GABA. The binding of BZs and Z-drugs alters the duration of IPSCs, primarily determined by the α 
subunit present in the GABAA receptor subtypes they bind to (for review, Möhler et al., 2002).  
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 The specificity of sedative-hypnotic drugs for distinct GABAA receptor subtypes is usually 
characterized in vitro, using Xenopus oocytes or cell systems expressing recombinant GABAA 
receptors. Animal models have proved to be a powerful tool to assess in vivo the drugs’ specificity for 
the various GABAA receptor subtypes (discussed in section 4).  
 
 
3.2. Effects of sedative-hypnotics on sleep physiology. 
Vigilance states (i.e., waking, sleep) are characterized by complex patterns of brain activity 
reflected by the electroencephalogram (EEG). Sleep is divided into two distinct stages: NREM sleep 
and REM sleep. In humans, NREM sleep is further subdivided into 4 stages 1-4 according to the 
predominance of slow waves. In stage 2, the frequency of brain waves is reduced and EEG hallmarks 
called spindles occur. Responsiveness to stimuli decreases as EEG slow waves become more 
predominant. Thus, stages 3 and 4, also referred to as “deep” sleep or “slow-wave” sleep, are 
characterized by high amplitude slow waves. 
Each vigilance state has its EEG signature. Quantitative EEG analysis allows the extraction of 
important functional parameters such as slow-wave-activity (SWA, or “delta” activity) in NREM 
sleep, encompassing components of the EEG signal in the frequency range of approximately 0.5-4.5 
Hz. SWA is considered as an indicator of sleep “depth” or “intensity”. The amplitude of slow waves 
occurring after sleep onset, and reflected by SWA, depends on the amount of time previously spent 
awake (Borbély et al., 1981). After a night’s sleep, slow waves show markedly decreased amplitude in 
the morning. Interestingly, individuals showing a lower proportion of deep sleep are more likely to 
self-medicate (Roth, 2007). NREM sleep stage 2 is characterized by spindle activity, defined as power 
in the frequency range between ~12-15 Hz. The functional significance of slow waves and spindles is 
still unknown. REM sleep and waking are characterized in animals (i.e., rodents) by a pronounced 
activity in the theta (6-9 Hz) frequency range.  
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 Ideally, a hypnotic drug should, reduce the latency to sleep onset, reduce waking after sleep onset, 
enhance aspects of sleep such as NREM sleep duration and SWA, without affecting sleep architecture 
(i.e., the alternation of NREM-REM sleep cycles). The mechanism of action of drugs traditionally 
used to treat insomnia, and their effects on sleep, are summarized below. Drugs which recently 
received considerable attention for their potential to treat insomnia (THIP/gaboxadol, Tiagabine), and 
other GABAA modulators studied for their effects on sleep (e.g., alcohol, neurosteroids) are also 
discussed.  
 
3.2.1. Positive allosteric modulators mainly target synaptic γ2-containing GABAA receptors mediating 
phasic inhibition.  
Historically, barbiturates were the first widely prescribed sedatives in the early 1900s. At low 
concentrations, they act as positive allosteric modulators of GABAA receptors, at a binding site 
distinct from that of BZs. At high doses, they directly act at the GABA binding site. Due to their 
toxicity and development of tolerance and dependency, their prescription and use as hypnotics has 
been discontinued. Barbiturates markedly alter the EEG in NREM sleep, especially reducing activity 
<10 Hz. In contrast, frequency components above 10 Hz, encompassing the spindle frequency range 
are increased. Barbiturates also increase NREM sleep duration and suppress REM sleep (Lancel, 
1999).  
Classical BZs (e.g., diazepam (valium), flunitrazepam (Rohypnol®), flurazepam 
(Dalmadorm®), triazolam (Halcion®), midazolam (Dormicum®)) were introduced in the 60s. They 
were widely prescribed due to their potent anxiolytic and sedative properties. Importantly, BZs lacked 
the toxicity of barbiturates, as well as the liability of overdose due to their pharmacokinetics (Visser et 
al., 2003; Mendelson, 2005). BZs act at α1, α2, α3 and α5 subtypes containing the γ2 subunit, while 
α4 and α6 subtypes are insensitive to BZs (Table 1) (Möhler et al., 2002). Thus, BZs target the 
majority of GABAA receptors, producing sedative, anxiolytic, muscle relaxant, anticonvulsant and 
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 cognition-impairing effects. The slow-elimination of various compounds (e.g., flunitrazepam, 
flurazepam) was linked to residual effects such as daytime sleepiness and impaired performance. 
Compounds with a shorter half-life were then developed (e.g. triazolam, midazolam) and seemed to 
lack residual side-effects (Borbély et al., 1983a). BZs reliably shorten sleep onset latency and increase 
sleep continuity. REM sleep is typically reduced and REM sleep latency prolonged (Borbély et al., 
1991; Mendelson, 2005; Lemmer, 2007). All compounds induce dramatic reduction of the EEG power 
in the low frequencies (< 10 Hz), encompassing SWA (~0.5-4.5 Hz), while spindle activity is 
increased (Fig. 3 and 4). These significant changes persisted in the subsequent “drug-free” night 
(Borbély et al., 1983b; Borbély et al., 1991). The clinical and functional significance of 
pharmacologically suppressing vigilance states and altering the EEG is uncertain. Interestingly, the 
typical declining trend of SWA over consecutive NREM sleep episodes is not altered by BZs, 
suggesting that the homeostatic process of sleep regulation is not disrupted (Borbély & Achermann, 
1991). Usage of BZs is curtailed by their side-effects, such as next-day sedation, cognitive impairment 
and amnesic effects (Fig. 4; for review, Korpi et al., 1997). Their long-term use can also lead to 
development of tolerance and dependence, as well as rebound symptoms at withdrawal (Roehrs et al., 
1990; O'Brien C, 2005; Stewart, 2005). These side effects, together with the need for a more restricted 
activity profile, have led to the screening of novel compounds also acting at GABAA BZ-binding site. 
The generation following the BZs, known as “Z”-drugs, was launched in the 80s. This new 
class of drugs includes imidazopyridines (zolpidem, Stilnox®, Ambien®, generics available), 
cyclopyrrilones (zopiclone; eszopiclone, S-enantiomer of zopiclone, Lunesta®), pirazolopyrimidines 
(zaleplon, Sonata®). Indiplon (a derivative of zaleplon) and eszopiclone are currently under review by 
the US Food and Drug administration for their potential in treating insomnia. Z-drugs are structurally 
different from the BZs. However, they act on the same binding site. They display high potency at α1-
containing receptors, medium potency at α2 and α3-containing receptors and lack of interaction at the 
α5-subtype (Dämgen & Lüddens, 1999). Overall, Z-drugs show similar actions on sleep as BZs, 
including the shortening of latency to sleep and a dose-dependent reduction of REM sleep (Fig. 4) 
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 (Brunner et al., 1991; Lader, 1992). Strikingly, Z-drugs share the “spectral EEG signature” of BZs, 
i.e., consistent reduction of low EEG components (<10 Hz) comprising the SWA range, and an 
increase in EEG power in the spindle frequency range during NREM sleep (Trachsel et al., 1990; 
Brunner et al., 1991; Aeschbach et al., 1994). The dynamic pattern of SWA and spindle frequency 
activity within NREM sleep episodes were also shown to be preserved after administration of Z-drugs 
(Aeschbach et al., 1994). 
These findings suggest that drugs acting at the BZ’s binding site do not interfere with the 
homeostatic aspect of sleep regulation, but rather with EEG generating mechanisms (Borbély et al., 
1991). Overall, while Z-drug hypnotics represent effective sleeping aids, concerns remain regarding 
their side-effects. In particular, amnesia and risk of tolerance and dependence occur when these 
compounds are used over an extended period of time (George, 2001). 
 
3.2.2. Effects of drugs modulating tonic inhibition. 
Recent studies emphasize the potential role of extrasynaptic receptors in the modulation of 
sleep. A selective GABAA agonist, THIP (4, 5, 6, 7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol; 
gaboxadol) was recently investigated for its potential to treat insomnia. Moreover, several compounds 
studied for their sedative-hypnotic actions have been characterized as endogenous (e.g., neuroactive 
steroids) or exogenous (e.g tiagabine, alcohol) modulators of GABAA-tonic conductance. 
THIP (gaboxadol) is a relatively old compound. It is a derivative of muscimol sharing a 
similar structure with GABA (Krogsgaard-Larsen et al., 1977). In a Xenopus oocyte recombinant 
expressing system, THIP acts as a low-potency agonist at α1β3γ2 subtype and is a partial agonist at 
α4β3γ2 (Brown et al., 2002; Krogsgaard-Larsen et al., 2004). However, it is a full agonist at α4β3δ 
receptors and generates currents larger than those produced by GABA (Brown et al., 2002; Storustovu 
& Ebert, 2006). The presence of δ subunit was shown to be a strong determinant of the increased 
pharmacological activity of agonist compounds, while the presence of γ subunit precludes the response 
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 to an agonist (Storustovu & Ebert, 2006). The exquisite selectivity of THIP is used as a tool to identify 
tonic currents in electrophysiological studies. THIP effects on sleep differ substantially from those 
induced by allosteric modulators (Fig. 3 and 4). Several studies in human subjects reported a decrease 
of wakefulness after sleep onset and/or an increase in total sleep time, while REM sleep was not 
altered. THIP also induced an increase in EEG power encompassing SWA, and a selective decrease in 
the spindle frequencies during NREM sleep (Faulhaber et al., 1997; Lancel et al., 2001; Mathias et al., 
2001a; Mathias et al., 2005; Walsh et al., 2007; Lankford et al., 2008). This compound was 
discontinued in March 2007 while it was in Phase III clinical trial. Nonetheless, THIP is a powerful 
tool to investigate the role of the unique GABAA receptor populations composed of δ-containing 
receptors (discussed in Section 4).  
Another compound, tiagabine, has been recently investigated for its potential as a hypnotic. 
Tiagabine is a GABA uptake inhibitor launched initially as an anticonvulsant in treatment of epilepsy. 
It specifically inhibits the GABA transporter GAT-1 (Fig. 1). Such pharmacological manipulation may 
sustain synaptically-released GABA levels in the synaptic cleft, thereby increasing GABAA-mediated 
inhibition as well as activation of GABAB receptors. The effects of tiagabine on sleep are similar to 
those evoked by selective GABA
B
A agonists. Indeed, tiagabine elevates EEG power density in 
frequencies <10 Hz during NREM sleep, including the SWA range (Mathias et al., 2001b), and 
increases sleep continuity and time spent in NREM sleep stage 3-4 (Mathias et al., 2001b; Walsh et 
al., 2005; Roth et al., 2006; Walsh et al., 2006a; Walsh et al., 2006b).  
Neuroactive steroids represent a major group of endogenous modulators of GABAA (Belelli & 
Lambert, 2005). Extrasynaptic α4βδ receptors are sensitive to positive allosteric modulation by 
neurosteroids of the pregnane class (Mihalek et al., 1999; Adkins et al., 2001; Brown et al., 2002; 
Wohlfarth et al., 2002). Hence, endogenous neurosteroids can selectively enhance GABAA-mediated 
tonic conductance (Stell et al., 2003; Herd et al., 2007). The scarce studies addressing the effects of 
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 neuroactive steroids on sleep-wake behavior suggest that different compounds exert distinct effects on 
sleep (for review, Lancel, 1999; Steiger, 2007). 
Alcohol is also a potential allosteric modulator of extrasynaptic GABAA receptors. Its use to 
counteract difficulties to sleep is fairly common (Johnson et al., 1998). δ-GABAA receptors may be 
sensitive to low ethanol concentrations (Sundstrom-Poromaa et al., 2002; Wallner et al., 2003; Wei et 
al., 2004). However, the demonstration of the selective action of ethanol on the δ subtype awaits 
further confirmation since recent studies found no effects of alcohol on these receptors (Borghese et 
al., 2006; Korpi et al., 2007). Ethanol increases EEG power in the low 0.25-1 Hz frequency range in 
NREM sleep, while EEG power in the spindle frequency range is decreased (Dijk et al., 1992). The 
increase in frequencies below 1 Hz is interesting since they comprise slow (<1 Hz) oscillations, an 
EEG hallmark of sleep. Slow oscillations in thalamo-cortical neurons correspond to the slow 
membrane potential oscillation consisting of up and down states (Steriade et al., 1993a; Steriade et al., 
1993b; 1993c). The effects of ethanol differ from those of BZs, Z-drugs and selective GABAA 
agonists. 
 
Overall, allosteric modulators acting at γ2-containing GABAA receptors reduce sleep latency 
and sleep fragmentation. They alter sleep architecture, promoting NREM sleep while suppressing 
REM sleep. Furthermore, nearly all BZs and Z-drug compounds reduce SWA and increase spindle 
occurrence. In contrast, drugs modulating extrasynaptic δ-containing receptors do not alter sleep 
latency, may increase sleep continuity depending on the dose administered, and increase EEG power 
in the SWA range (Fig.4). These diverse effects on sleep are due to the pharmacokinetics and the 
neuronal networks targeted by sedative-hypnotic drugs. This raises the interesting possibility that 
activation of synaptic GABAA receptors by allosteric modulators plays a role in mechanisms 
underlying induction/consolidation of NREM sleep and spindles, while suppressing mechanisms 
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 triggering REM sleep and processes underlying slow wave generation. On the other hand, 
extrasynaptic receptors mediating tonic inhibition may be involved in EEG synchronization. 
 
 
4. Dissection of the role of GABAA receptors in sleep and sleep regulation: insights from animal 
models and pharmacology 
Deciphering the sedative-hypnotic properties of drugs modulating either synaptic or extrasynaptic 
GABAA receptors relates to the functional analysis of the multiple GABAA subtypes. The combination 
of pharmacological approaches with genetically-engineered mice (knock-in and knock-out (KO) mice) 
proved to be a powerful approach to investigate the function of distinct GABAA subtypes in mediating 
the effects of drugs. It certainly emphasized the importance of GABAA receptor heterogeneity. 
 
4.1. Which GABAA subtypes mediate the sedative-hypnotic effects of allosteric modulators acting at 
mainly synaptic GABAA receptors? 
Great progress was achieved in identifying the GABAA receptor subtypes involved in the effects 
of BZs and Z-drugs using genetically engineered mice. A point mutation (“knock-in”) in the α1, α2, 
α3, or α5 subunits was introduced to prevent the binding of diazepam at the BZ binding site (α4 and 
α6 subtypes being insensitive to BZs). Such point mutation preserves the physiological functions of 
the receptor, and consists of  replacing the conserved histidine residue, prerequisite to BZ binding, by 
an arginine residue (α1(H101R), α2(H101R), α3(H126R) and α5(H105R)) (Rudolph & Mohler, 2004). 
Studies using these knock-in mice showed that the α1 subtype mediates both sedative (Rudolph et al., 
1999; Crestani et al., 2000b; McKernan et al., 2000) and amnesic actions of the BZs (Rudolph et al., 
1999). On the other hand, muscle relaxant effects are mediated by α2 subtype and at high dose by α3 
receptors (Crestani et al., 2001). 
In contrast, characterizing which subtype(s) underlie(s) the hypnotic properties of BZs proved to 
be complex. The α1 subtype was expected to fulfill this role since it mediates the sedative actions of 
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 diazepam. However, α1-point mutated (H101R) mice displayed a similar response to diazepam (3 
mg/kg) compared to control mice (Tobler et al., 2001). In particular, action of diazepam on sleep 
latency, amount of sleep and suppression of REM sleep does not require the α1 subtype. Strikingly, 
the reduction of SWA induced by diazepam was even more pronounced in α1(H101R) mice. Sleep 
continuity was enhanced by diazepam only in α1(H101R) mice, suggesting the involvement of other 
GABAA subtypes. The α3-subtype does not appear to mediate the effects of diazepam on sleep 
architecture, as shown by studies on α3(H126R) mice and α1(H101R)/α3(H126R) double mutant mice 
(Kopp et al., 2003; Kopp et al., 2004b). In α2(H101R) mice, the diazepam-induced decrease of SWA 
activity in NREM sleep was reduced compared to control mice, as well as the enhancement of theta 
activity in REM sleep (Kopp et al., 2004a). These findings suggest that α2-containing receptors, in 
particular those expressed in the hypothalamic and pontine ascending pathways, are involved in the 
generation of NREM sleep. The α2-subtype is also localized in the brainstem-septo-hippocampal 
systems involved in the generation of theta oscillations (Table 1 & Fig. 2) (Wisden et al., 1992; 
Fritschy & Mohler, 1995; Vertes & Kocsis, 1997; Jones, 2005; Luppi et al., 2006). Overall, these data 
indicate that the sedative and hypnotic actions of diazepam are dissociated and mediated by different 
neuronal circuits.  
 
Whereas diazepam and other BZs have a high affinity for α1, α2, α3 and α5-subtypes, zolpidem 
has a 10-fold higher affinity for α1- than for α2- and α3-subtypes and does not recognize the α5-
subtype (Dämgen & Lüddens, 1999). Knock-in mice confirmed in vivo its preferential affinity for the 
α1-subtype. Sedative effects of zolpidem are mediated through the α1-subtype (Crestani et al., 2000a). 
The in vivo contribution of the γ2 subunit to the actions of zolpidem was also confirmed in point 
mutated γ2(F77I) mice (Cope et al., 2004). Regarding the hypnotic actions of zolpidem, α1(H101R) 
mice did not show the marked reduction in SWA observed in control mice (Kopp et al., 2004b). In 
contrast, the drug induced an increase in NREM sleep and suppression of REM sleep in both 
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 genotypes. These data suggest that zolpidem-promoting effects on sleep are mediated by α2 and/or α3 
subtypes, whereas its effects on the sleep EEG are mediated by the α1 subtype.  
 
 
4.2. Further characterization of drugs acting at extrasynaptic receptors on sleep and the sleep EEG 
The full GABAA agonist THIP is a powerful compound to assess the involvement of tonic 
conductance in sleep and further investigate its effects on the sleep EEG. We used a knock-out mice 
model (δ-subunit KO) to assess whether the effects of THIP on sleep and the sleep EEG are mediated 
in vivo by the extrasynaptic δ-subtype. After THIP administration, δ-KO mice lacked the massive 
alterations of the EEG and vigilance states observed in wild-type control mice, demonstrating that the 
effects of THIP on vigilance states are mediated in vivo by the extrasynaptic δ-containing receptors 
(Winsky-Sommerer et al., 2007). In control mice, THIP did not shorten sleep latency but rather 
reduced the amount of NREM sleep. At higher doses, REM sleep was suppressed (Vyazovskiy et al., 
2005; Winsky-Sommerer et al., 2007; Alexandre et al., 2008). Strikingly, THIP consistently induced 
an abnormal EEG pattern (i.e., recurrent spike wave events, Fig. 3), resulting in a massive increase of 
EEG power in both waking and NREM sleep in the low frequencies encompassing the SWA range 
(Vyazovskiy et al., 2005; Winsky-Sommerer et al., 2007; Alexandre et al., 2008). This increase in 
power may be misleading. One should be aware that the recurrence of spike-wave events, at a 
frequency of approximately 0.5-1 Hz, as well as their asymmetric shape and high amplitude of the 
waves, largely contributed to the increase in SWA (Vyazovskiy et al., 2005). An abnormal EEG 
pattern was observed in the rat, also there contributing to the increase in SWA (Lancel & Faulhaber, 
1996; Lancel, 1997).  
High amplitude EEG spike-waves seem to be a common feature of drugs enhancing GABAA-
mediated tonic conductance (Fig. 3). Muscimol, another selective GABAA agonist showing very high 
affinity for δ-containing receptors (Quirk et al., 1995; Huh et al., 1996; Mihalek et al., 1999), induced 
such EEG patterns in several species (Pedley et al., 1979; Fariello et al., 1981; Peeters et al., 1989; 
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 Lancel et al., 1996; Lancel et al., 1997; Vyazovskiy et al., 2007). Tiagabine was reported to elicit 
similar alterations of the EEG (Walton et al., 1994; Coenen et al., 1995; Lancel et al., 1998). It is 
tempting to draw parallels with spike-wave events induced by the anesthetic etomidate (Reynolds et 
al., 2003) or the neuromodulator γ-hydroxybutyrate (Kaupmann et al., 2003; Meerlo et al., 2004; 
Vienne & Tafti, 2008). Etomidate is a potent modulator of extrasynaptic GABAA receptors (Belelli et 
al., 2005). In contrast, the effects of exogenous γ-hydroxybutyrate on sleep result from activation of 
the GABAB receptors which also mediate a slower type of transmission (Bowery, 2006; Vienne & 
Tafti, 2008).  
B
This drug-induced spike-wave activity was reported to be accompanied by a sedated 
behavioral state (Walton et al., 1994; Meerlo et al., 2004; Vyazovskiy et al., 2005; Vyazovskiy et al., 
2007; Winsky-Sommerer et al., 2007; Alexandre et al., 2008; Vienne & Tafti, 2008). During the 
catalepsy-like state induced by muscimol, spike-waves occur synchronously in the frontal and parietal 
EEGs (Vyazovskiy et al., 2007). This synchronous occurrence of high amplitude waves across cortical 
areas induced by muscimol is consistent with recent data suggesting an important role of inhibitory 
neurons in the large-scale synchronization of the slow <1 Hz oscillation in membrane potential 
undergone by cortical neurons during sleep (Volgushev et al., 2006).  
Overall, drug-induced increase of GABAA tonic conductance resulted in dramatic EEG 
alterations. This “excessive” conductance is inherent to the high sensitivity of GABAA agonists 
compared to GABA (Storustovu & Ebert, 2006). It was shown that relatively minor changes in 
chloride concentrations within the postsynaptic neurons can lead to a switch from hyperpolarizing to 
depolarizing activity. Thus, the effects of drugs acting at extrasynaptic receptors (THIP, muscimol, 
tiagabine, etomidate), especially in the thalamo-cortical networks, may result in quite profound 
alterations in properties of the networks. Furthermore, these findings suggest that tonic inhibition can 
easily be shifted outside the homeostatic range. Thereby, the dose-window of drugs acting directly at 
extrasynaptic GABAA receptors will be inevitably narrow. In the same line, GABA is a high affinity 
but low-efficacy agonist at extrasynaptic δ-containing receptors emphasizing the impact of 
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 endogenous modulators of tonic inhibition. For instance, neuroactive steroids may have profound 
effects by enhancing the efficacy of GABA (Stell et al., 2003; Belelli & Lambert, 2005). In the 
opposite situation, loss of tonic conductance in thalamo-cortical networks might induce seizure 
activity if such conductance is critical to limit increased excitability. δ-KO mice showed some seizures 
episodes (Olsen et al., 1997), suggesting an increased excitability or impaired inhibitory timing within 
the thalamus (Porcello et al., 2003).  
 
General anesthesia and sleep depress consciousness. They may share common 
neurophysiological elements (Tung & Mendelson, 2004; Franks, 2008). Although anesthetics are 
beyond the scope of this review, it is noteworthy that a number of them (e.g, etomidate, propofol, 
isoflurane) have been recently described as potent modulators of extrasynaptic GABAA δ-containing 
receptors (Bonin & Orser, 2008). The use of genetically-engineered mice has also played a critical role 
in distinguishing the role of specific GABAA subtypes in mediating their sedative, anesthetic and 
amnesic actions (Rudolph & Mohler, 2004).  
 
 
4.3. Evaluate the role of GABAA receptors expressed in specific neuronal networks  
Knock-out mice lacking distinct GABAA subunits exhibit compensatory changes. For instance, 
α1-KO mice show major alterations in the expression of several GABAA subtypes to compensate for 
the loss of expression of the α1 gene (Sur et al., 2001; Kralic et al., 2006). These compensatory 
changes may thereby preclude the dissection of each subtype’s contribution to an observed sleep 
phenotype. 
However, such potential caveats uncovered adaptative mechanisms. For instance, studies in α6-
KO mice showed that the loss of tonic inhibition due to the lack of extrasynaptic α6βδ receptors was 
compensated for, underlining the importance of tonic inhibition in the cerebellar granule cells. The 
compensatory mechanism was identified as an increased expression of the TASK-1 potassium channel 
21 
 which also inhibits cellular excitability in a continuous “tonic” manner (Brickley et al., 2001). The 
opposite studies were recently performed, analyzing the consequences of the loss of TASK-1 
potassium conductance. TASK-1 KO mice showed an increased impact of the GABAA receptor 
activation. Moreover, TASK-1 female KO mice were more affected by THIP compared to controls, 
while males showed similar responses in both genotypes. These findings suggest that a sex-dependent 
regulation of extrasynaptic GABAA receptors is involved in the changes induced by TASK-1 deletion 
(Linden et al., 2008). 
 
The role of β3 and α3 subtypes in sleep regulation was particularly interesting to address due to 
their expression in the reticular nucleus of the thalamus (nRT; Fig. 2). As previously mentioned, 
typical oscillations in the sleep EEG are closely associated with specific patterns of neuronal activity 
arising from the thalamo-cortical networks. Hence, the progressive hyperpolarization of 
thalamocortical neurons occurring during the progression from waking to deep sleep results in 
fluctuations in the membrane potential, which are initially in the frequency range of sleep spindles and 
then of slow waves (Steriade, 2003). The nRT plays a pivotal role in the thalamo-cortical circuitry by 
providing the main inhibitory input onto the thalamic relay nuclei (Huguenard & Prince, 1994; Cox et 
al., 1996). Only 10 % of mice with a disruption of the β3-subunit survive (Homanics et al., 1997). 
They display symptoms reminiscent of the human Angelman syndrome, including hyperactivity, poor 
motor coordination, repetitive stereotypical behavior, seizures and EEG abnormalities (DeLorey et al., 
1998). In thalamic slices from β3-KO mice, GABAA inhibition was disrupted in the nRT and 
oscillatory synchrony dramatically intensified (Huntsman et al., 1999). A sleep study showed that 
consistent with the disrupted inhibitory transmission in the nRT, the usual increase of EEG power in 
the spindle frequency range at the transition of NREM sleep to REM sleep was reduced in β3-KO 
mice. Moreover, SWA during NREM sleep was significantly higher in the β3-KO mice (Wisor et al., 
2002). These findings are however difficult to interpret since the study is performed on a “survivor” 
population where compensatory mechanisms are likely to occur. 
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 The α3 subtype displays a restricted distribution and is predominantly expressed in several 
neuronal populations crucial for sleep (Fig. 2, Table 1). It is strategically located in the nRT, the 
cortical layer VI, as well as in the monoaminergic and serotonergic neurons of the brainstem and the 
cholinergic neurons of the basal forebrain. In α3-KO mice, no compensation of the α3-GABAA 
receptors by other α subtypes seemed to occur in the nRT (Studer et al., 2006). Baseline sleep 
recordings did not reveal any major differences between α3-KO mice and wild-type controls (Winsky-
Sommerer et al., 2008). Consistent with the results in β3-KO mice, we observed in α3-KO mice a 
reduced increase in power in the spindle frequency band (10–15 Hz) at the transition between NREM–
REM sleep. Furthermore, sleep pressure did not uncover differences in sleep regulation between the 
genotypes. The puzzling lack of sleep phenotype suggested compensatory mechanisms. Synaptic 
GABAA clustering plays is important for the function of inhibitory synapses. Strikingly, despite the 
disruption of postsynaptic GABAA receptor clusters in α3-KO mice, GABAA-mediated inhibition is 
retained in the thalamic reticular nucleus (Winsky-Sommerer et al., 2008). These findings indicate that 
other GABAA receptor subtypes are present. Since the ε subunit is coexpressed with α3, the 
compensatory mechanism could be due to this subtype (Moragues et al., 2000). The structure (subunit 
partner) and function of native GABAA receptors containing the ε subunit are unknown. This subtype 
shows a very discrete distribution and in particular in regions involved in sleep (Fig. 2, Table 1). It is 
predominantly expressed in the locus coeruleus and the hypothalamus, where 70 % of orexin neurons 
and 25 % of histaminergic neurons express the ε subunit mRNA (Sinkkonen et al., 2000; Sergeeva et 
al., 2005). It is also localized in the cholinergic and monoaminergic neurons, as well as the 
hippocampus (Whiting et al., 1997). Interestingly, the ε gene is clustered on the same chromosome 
(Xq28) as the α3 and θ genes (Whiting et al., 1999). The recombinant ε subtype has peculiar 
electrophysiological properties: it shows a high sensitivity to GABA, and seems to be insensitive to 
BZs, which is expected if it substitutes the γ subunit (Ranna et al., 2006). Presence of the ε subunit 
also reduced neurosteroid and anesthetic modulation (Davies et al., 1997; Belelli et al., 2002). 
Moreover, some findings are suggestive of spontaneous channel opening (Neelands et al., 1999; 
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 Maksay et al., 2003; Wagner et al., 2005), which would produce a tonic inhibition comparable to the 
one mediated by δ-containing receptors. Due to its expression in neuronal populations crucial for sleep 
and peculiar electrophysiological characteristics, it will be interesting to investigate the role of the ε-
subtype in sleep. These findings show that the adaptative changes taking place are sophisticated 
enough to sustain thalamo-cortical function underlying complex behaviors and related brain activity in 
α3-KO mice. The recent description of the imidazopyridine TP003 compound, which appears to be 
selective at the α3-containing receptors, may provide an alternative approach to investigate the role of 
the α3 subtype in sleep (Dias et al., 2005).  
 
Mice lacking the γ2 subunit die within the first 2 postnatal weeks. The number of BZ sites is 
reduced by 90 % in these mice, confirming that γ2 is necessary for BZ binding (Gunther et al., 1995). 
A sleep study in γ2-heterozygous mice did not reveal any difference in vigilance states or EEG 
hallmarks in these mice compared to their wild-type controls, suggesting the occurrence of 
compensatory mechanisms (I. Tobler, unpublished results). 
 
The use of knock-in and knock-out mice has provided considerable insights into the 
physiological, pharmacological and behavioral role of individual GABAA receptor subtypes, as well as 
the neurophysiological mechanisms underlying sleep. These studies emphasized the necessity to 
consider GABAA receptor-mediated transmission as a highly flexible process. This also revealed 
potent homeostatic mechanisms maintaining balance between excitation and inhibition in the CNS 
(e.g. α1-KO, α3-KO, α6-KO). New models allowing temporally and/or spatially controlled deletion of 
genes in mice will help refine the precision of analysis. Notably, a novel approach restoring drug 
sensitivity in chosen cell types was recently developed and may prove to be invaluable to investigate 
the role of specific GABAA subtypes and neuronal circuits (Wulff et al., 2007). Moreover, drugs that 
specifically target defined GABAA receptors are expected to provide new prospects for insomnia 
therapy and be used as tools to study sleep. 
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 5. GABAA receptors pharmacology: future prospects for the treatment of insomnia  
BZs and Z-drugs are the predominant hypnotics used in the treatment of insomnia. 
Meanwhile, multiple modes of GABA-mediated transmission have been characterized, i.e., the tonic 
conductance mediated by the extrasynaptic GABAA receptors, as well as GABAA subtype-dependent 
properties of phasic IPSCs. These distinct modes are localized in defined neuronal networks, in a cell-
specific manner, often operating in parallel in a given structure. These findings suggest the value to 
develop drugs based on the specificity for GABAA subtypes in distinct neuronal circuits. Moreover, 
since the tonic conductance may have profound effects on neuronal excitability and thereby network 
activity, further characterizing its physiological role in sleep is of importance. 
Three GABAA allosteric modulators are currently in clinical development: Indiplon-IR and -
MR (Immediate/Modified Release; developed by Neurocrine Biosciences) are awaiting approval from 
the US Food and Drug Administration. Indiplon is a derivative of zaleplon and shows a similar 
pharmacological profile, including selectivity for the GABAA α1 subtype (Neubauer, 2005; Marrs, 
2008). The EVT-201 compound (developed by Evotec) and Adipiplon (NG2-73; developed by 
Neurogen) are in phase II clinical trials. They both have the characteristic to be partial agonists at the 
BZ binding site. Interestingly, NG2-73 may modulate a more restricted set of neuronal networks 
involved in sleep, if its selectivity for the α3 subtype is confirmed. Only brief descriptions of their 
effects are available, and to date, no results have been published. 
The GABAA δ subtype has emerged as an important pharmacological target for insomnia. 
Novel compounds selectively acting as allosteric modulators of the δ subtype have been described 
very recently (Wafford et al., 2008). These compounds potentiate tonic currents mediated by the δ 
subtype. They may provide useful tools to assess in vivo the impact of tonic conductance in sleep and 
the benefits of its increase in a manner which, in contrast to selective agonists such as THIP or 
muscimol, may prove to stay within a homeostatic range. Further characterization of their actions on 
neurophysiology will provide important insights to predict the potential therapeutic effects of this class 
of drugs. Drugs effective in insomnia treatment should not impair daytime performance. Thus, in 
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 addition to sleep, these novel compounds will also be useful to assess the impact of tonic conductance 
on cognition.  
In the context of drugs targeting the GABA δ subtype, the interactions between neurosteroids 
and extrasynaptic receptors should be taken into consideration. They may predict a gender-specific 
drug responsiveness to the drug (Linden et al., 2008). Several findings indicate that neurosteroids 
exert a subtle regulation of extrasynaptic GABAA receptors (Herd et al., 2007). Fluctuations of 
circulating neurosteroids accompanying the oestrous cycle, gestation, or stress, induce profound and 
rapid alterations of the GABAA-mediated tonic conductance (Maguire et al., 2005; Maguire & Mody, 
2007; , 2008). 
GABAA receptors are subjected to a highly dynamic regulation, including multiple 
mechanisms such as phosphorylation, post-translational modifications, and regulation of receptor 
trafficking (Leidenheimer et al., 1991; Fritschy & Brunig, 2003; Luscher & Keller, 2004). In this line, 
agonist activation of GABAA receptors as well as chronic BZ treatment have been shown to increase 
GABAA receptor endocytosis (Tehrani & Barnes, 1991; Calkin & Barnes, 1994). Epigenetic 
mechanisms also modulate GABAA receptor expression in response to stressful stimuli. These 
emerging regulatory mechanisms could be relevant in the pathophysiology of insomnia. 
 
 
 
6. Conclusions. 
The heterogeneity of GABAA receptors, the emergence of tonic conductance, as well as the 
potent adaptive mechanisms taking place in genetically-engineered mice, provide attractive avenues to 
further investigate the role of GABAA receptors in the homeostasis of sleep. Understanding the 
mechanisms underlying physiological sleep may provide an optimal basis to develop novel GABAA 
subtype-selective compounds to treat sleep disorders, as well as to characterize their effects on the 
EEG and performance in human subjects. Because of the central role of GABAergic transmission on 
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 regulation of neuronal networks and complex behaviors, it would be of interest to investigate whether 
GABAA receptors function is altered in insomnia and/or undergo dynamic changes to maintain 
homeostasis in this sleep disorder.  
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 Abbreviations 
 
ACh: acetylcholine; ADO: adenosine; BZ: benzodiazepine; DA: dopamine; DpMe: deep 
mesencephalic reticular nucleus; DR: dorsal raphe nucleus; EEG: electroencephalogram; GABA: γ-
aminobutyric acid; Glu: glutamate; Hcrt: hypocretins/orexins; His: histamine; IPSCs: inhibitory 
postsynaptic currents; KO: knockout; LC: locus coeruleus; LDTg: laterodorsal tegmental nucleus; 
MCH: melanin concentrating hormone; NA: noradrenaline; n.d: non determined; NREM sleep: non 
rapid-eye movement sleep; nRT: reticular nucleus of the thalamus; PeF: perifornical nucleus. PH: 
posterior hypothalamus area; PPTg: pedunculopontine tegmental nucleus; SubC: subcoeruleus 
nucleus; SWA: slow-wave activity; TM: tuberomammillary nuclei; VLPAG: ventrolateral 
periacqueductal gray; VLPO: ventrolateral preoptic area; 5-HT: serotonin. 
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 Table 1. Characteristics of the main GABAA receptor subtypes. 
Subunit 
composition 
Expression in specific cell types Subcellular distribution GABAA-mediated 
transmission 
Ligands relevant in sleep 
α1β2γ2 -Cortex, hippocampus : principal cells & 
interneurons  
-Thalamus: relay neurons 
-Pallidum, substantia nigra: GABAergic 
neurons 
-Cerebellum: Purkinje cells, stellate, basket 
cells & granule cells 
synaptic, extrasynaptic phasic / tonic BZ, Z-drugs 
α2β3γ2 -Hippocampus: principal cells 
-Striatum: spiny stellate neurons 
-Inferior olivary neurons 
-Motoneurons 
synaptic, extrasynaptic Phasic / tonic BZ, Z-drugs 
α3βxγ2 -Cortex: principal cells in layers V-VI 
-Basal forebrain cholinergic neurons 
-Thalamus: reticular thalamic neurons 
-Brainstem: serotonergic (dorsal raphe) & 
noradrenergic (locus coeruleus) neurons 
-Cerebellum: Golgi cells 
-Inferior olivary neurons 
synaptic, extrasynaptic phasic/ tonic BZ, Z-drugs 
α4β2γ2 
 
α4βxδ 
-Hippocampus: dentate gyrus granule cells 
-Thalamus: relay neurons 
-Hippocampus: dentate gyrus granule cells 
-Thalamus: relay neurons 
synaptic*, extrasynaptic* 
 
extrasynaptic* 
phasic / tonic 
 
tonic 
Insensitive: BZ- & Z-drugs 
 
Insensitive: BZ- & Z-drugs 
Selective GABAA agonists, 
Neurosteroids, 
Ethanol? 
α5βxγ2 -Hippocampus: granule cells 
-Spinal trigeminal neurons 
synaptic, extrasynaptic phasic / tonic BZ 
α6βxγ2 
α6βxδ 
Cerebellum: granule cells 
Cerebellum: granule cells 
synaptic 
extrasynaptic 
phasic 
tonic 
Insensitive: BZ- & Z-drugs 
Insensitive: BZ- & Z-drugs 
Ethanol? 
ε-subtype -Septum: GnRH neurons 
-Basal forebrain: cholinergic cells 
-Hypothalamus: hypocretinergic, 
histaminergic, oxytocinergic, dopaminergic 
neurons 
-Brainstem: dopaminergic (substantia 
nigra), serotonergic (raphe nuclei) & 
noradrenergic (locus coeruleus) neurons 
n.d tonic Insensitive: BZ 
θ-subtype -Hippocampus: dentate gyrus granule cells 
-Basal forebrain: cholinergic cells 
-Hypothalamus: dopaminergic neurons 
-Brainstem: serotonergic & noradrenergic 
(locus coeruleus) neurons 
n.d n.d n.d 
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 GnRH: gonadotropin-releasing hormone; n.d: not determined. x: subunit isoform undetermined. ?: 
matter of debate. *: scarce neuromorphological evidence. For the regional and cellular expression of 
GABAA subtypes, see (Bonnert et al., 1999; Moragues et al., 2000; Möhler et al., 2002; Moragues et 
al., 2002; Fritschy & Brunig, 2003). 
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 Figure legends 
 
Figure 1. Scheme of a GABAergic synapse and diversity of GABA-mediated transmission. 
GABA released in the synaptic cleft exerts its action via presynaptic and postsynaptic GABAA as well 
as GABAB receptors. Binding of GABA at synaptic GABAB A receptors results in inhibitory 
postsynaptic currents (IPSCs) which transiently inhibit neurons for 10-100 ms. In contrast, activation 
of extrasynaptic GABAA receptors mediates tonic currents, playing a key role in adjusting membrane 
conductance. GABA transporters (GAT-1, GAT-3) can operate in a bidirectional way (i.e., remove 
GABA from the extracellular space or provide a source of GABA), thereby potentially modulating 
tonic inhibition. Synaptic and extrasynaptic receptors, which underlie these two forms of transmission, 
differ in their structural composition, subcellular localization, as well as electrophysiological 
characteristics, resulting in distinct pharmacological and functional properties. 
 
Figure 2. Expression of GABAA subtypes in major structures and neurotransmitter systems 
involved in the regulation of vigilance states. 
In blue, predominant GABAA subtype; In black, other subtype(s) present. Red stars indicate regions 
where tonic currents were identified by electrophysiology. The activity of the major neuronal networks 
involved in waking, NREM and REM sleep is reviewed elsewhere (Jones, 2005; Luppi et al., 2006). 
ACh, acetylcholine. ADO, adenosine. DA, dopamine. DpMe, deep mesencephalic reticular nucleus. 
DR, dorsal raphe nucleus. Glu, glutamate. Hcrt, hypocretins/orexins. His, histamine. LC, locus 
coeruleus. LDTg, laterodorsal tegmental nucleus. MCH, melanin concentrating hormone. NA, 
noradrenaline. n.d: non determined. nRt, reticular nucleus of the thalamus. PeF, perifornical nucleus. 
PH, posterior hypothalamus area. PPTg, pedunculopontine tegmental nucleus. SubC, subcoeruleus 
nucleus. TM, tuberomammillary nuclei. VLPAG, ventrolateral periacqueductal gray. VLPO, 
ventrolateral preoptic area. 5-HT, serotonin. 
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 Figure 3. Representative examples of 12-sec electroencephalogram traces (frontal EEG) and 
EEG power spectra, during waking and NREM sleep, following administration of vehicle or 
sedative-hypnotic drugs in mice.  
Benzodiazepines and Z-drugs (e.g., diazepam 3 mg/kg and zolpidem 5 mg/kg, respectively; in blue) do 
not induce visually observable changes at the level of the raw EEG compared to the placebo condition 
(i.e., vehicle; in black). In contrast, after administration of a low dose of two GABAA agonists 
(muscimol (2 mg/kg) or THIP (4 mg/kg); in red), the EEG pattern is characterized, both during waking 
and NREM sleep, by recurring spike-wave events. Muscimol and THIP both act as superagonists at 
the δ-subtype. By enhancing tonic conductance, both drugs dramatically altered the brain electrical 
activity. Spectral analysis reveals profound alterations induced by sedative-hypnotic drugs in the EEG 
activity. GABAA allosteric modulators (e.g. diazepam) and GABAA agonists (e.g., THIP) induce 
opposite changes on the NREM sleep EEG spectra, illustrated for the first 90 minutes after drug 
administration. The slow-wave activity increase induced by THIP, both in the waking and NREM 
sleep spectra, is largely due to the recurring spike-events observed at the raw EEG level. Gray bars 
indicate the slow-wave activity frequency range (~0.5-4. Hz) and the spindle frequency range (~10-15 
Hz). 
 
Figure 4. Overview of the effects induced by sedative-hypnotic drugs on sleep and other 
parameters, depending which GABAA subtypes the drugs target.  
Blue and red indicate γ2- and δ-subtype, respectively. Freq: frequency. 
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